Good MorningEquity markets pulled back for Wednesday's 3rd day this week as a growing fear of an economic downturn saps bullish sentiment. The downturn, which has been expected for several quarters, appears to be finally here based on guidance from retailers like Target and Lowe's. In their view, consumer spending will fall double-digit this year, on top of a 30% correction in the housing market—demand for mtg fells to a 28-year low and points to a deepening correction in that sector.
On the bright side, not all is lost in the investing world. While most of the S&P 500 index is under pressure, some sectors, like fast food, are producing growth and guiding for growth in 2023. These stocks offer investors a range of opportunities, including blue chip safety, high yield, and value, depending on where you look. Featured: President Trump’s Project MAFA (Ad) 
|
Tech | | | After sweeping through battles in statehouses across the country, the war against ESG investing is heating up in Congress.
The Senate voted Wednesday to overturn a Labor Department rule allowing retirement plans to consider environmental, social and governance factors when making inve... Read the Full Story |
|
From Our Partners | | Bitcoin just smashed through $122,000 — exactly as crypto analyst Juan Villaverde predicted.
Now he says it’s headed for $150K… but believes one lesser-known coin could outperform Bitcoin entirely. He’s sharing the name and setup behind it — just as we enter what he calls the biggest crypto bull run in history. | | See the coin Juan says could beat Bitcoin in this bull market |
|
Stocks | | |
A high dividend yield can be an attractive feature, as it’s a way of gauging a stock’s dividend payout relative to its price. Some of the highest yields can be found in oil-and-gas master limited partnerships and tanker companies, but you can also get high yields from many other sector... Read the Full Story |
|
Stocks | | | Stocks are rising Monday, clawing back some of their losses from Wall Street’s worst week since early December.
The S&P 500 was 0.6% higher in afternoon trading and on pace for just its second gain in the last seven days. The Dow Jones Industrial Average was up 146 points, or 0.5%... Read the Full Story |
|
From Our Partners | | After 43 years as a professional trader, Jeff Clark has walked away from traditional investing — and he’s not looking back.
Instead, he’s using a strategy that delivered 18 wins out of 18 trades in 2025… with instant payouts of $100 to $1,000 each time — no stock ownership required. He explains it all in a free instructional video. | | Watch how to collect your first payout here |
|
Stocks | | | Stocks steadied themselves Monday following Wall Street's worst week since early December.
The S&P 500 rose 12.20 points, or 0.3% to 3,982.24 for just its second gain in the last seven days. The Dow Jones Industrial Average gained 72.17, or 0.2%, to 32,889.09, while the Nasdaq com... Read the Full Story |
|
Markets | | |
Jack in the Box (NASDAQ: JACK) CEO Darrin Harris has this company wound up and ready to spring into growth. He has been rationalizing operations across the system, focusing on building the franchise network and growing into new markets. His efforts include menu choices and standardizations, a push... Read the Full Story |
|
From Our Partners | | A couple of years ago, we started playing with the massive amounts of data that MarketBeat takes in everyday trying to figure out if there was a way to identify short term trading wins. By analyzing earnings data, news sentiment, analyst recommendations, insider transactions and dozens of other data points, we think we’ve found an algorithm that finds interesting short-term stock ideas. We call that algorithm the IdeaEngine and its stock ideas are published on MarketBeat All Access every Monday morning. We make one IdeaEngine idea available free every Monday as an SMS alert. We’ll be releasing the next IdeaEngine alert on Monday morning, so make sure you are signed up before then.  | | Get MarketBeat IdeaEngine Alerts (Free) |
|
Stocks | | | Stocks are opening higher, clawing back some of the losses from their worst week since early December. The S&P 500 rose 0.8% early Monday and is on pace for just its second gain in the last seven days. The Dow and the Nasdaq also rose. Stocks have struggled in February after a strong start to th... Read the Full Story |
|
Markets | | | Wall Street pointed toward gains before the opening bell Monday after last week's rout and ahead of another full slate of corporate earnings this week.
Futures for the benchmark S&P 500 rose 0.5% and futures for the Dow Jones industrials moved 0.4% higher.
Last week... Read the Full Story |
|
Markets | | |
Plug Power’s (NASDAQ: PLUG) Q4 and FY results have the shares moving sharply lower, but this is a knee-jerk reaction to headline news. The results were weaker than expected but should not have been a surprise given the early phase of the business. Start-ups across sectors, industries, and ve... Read the Full Story |
|
Markets | | |
Target Corporation’s (NYSE: TGT) shares were down more than 4% in Wednesday’s session, despite the retailer beating the headline expectations in their earnings report yesterday. As initial reactions go to quarterly updates, you’d be forgiven for thinking it was an odd one, but on... Read the Full Story |
|
Markets | | |
Shares of Rivian Automotive, Inc. (NASDAQ: RIVN) are down more than 17% the day after the company delivered a disappointing earnings report. The results were mixed and not altogether poor, but they were still enough to give investors a taste of consumers' anxiety about electric vehicles.
Ri... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. | | View Today's Stock Pick |
|
